We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$3.46B
Cap. Flow %
-15.95%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Miscellaneous 21.83%
3 Communication Services 8.41%
4 Technology 5.7%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
51
Abivax
ABVX
$9.95B
$16.3M 0.08%
122,000
+120,000
+6,000% +$13.6M
VNET
52
VNET Group
VNET
$1.75B
$16M 0.07%
1,992,000
+1,368,653
+220% +$12.4M
NTES icon
53
NetEase
NTES
$74.9B
$15.8M 0.07%
123,500
-167,719
-58% -$19.8M
BIIB icon
54
Biogen
BIIB
$33.2B
$15.3M 0.07%
+71,000
New +$13.6M
TSHA icon
55
Taysha Gene Therapies
TSHA
$1.81B
$15.3M 0.07%
+2,250,000
New +$13.3M
MOBI
56
Mobia Medical
MOBI
$387M
$15.1M 0.07%
+1,128,557
New +$14.6M
NERV icon
57
Minerva Neurosciences
NERV
$224M
$13.1M 0.06%
2,365,000
– –
ALMR
58
Alamar Biosciences
ALMR
$2.12B
$12.5M 0.06%
+462,900
New +$10.5M
ALVO icon
59
Alvotech
ALVO
$1.92B
$10.6M 0.05%
2,859,675
+2,660,000
+1,332% +$9.51M
BBNX
60
Beta Bionics
BBNX
$896M
$9.32M 0.04%
595,000
-3,012,920
-84% -$35.8M
IFRX icon
61
InflaRx
IFRX
$329M
$7.45M 0.03%
+3,325,000
New +$6.25M
SMG icon
62
ScottsMiracle-Gro
SMG
$3.45B
$5.99M 0.03%
+88,000
New +$5.45M
WAY
63
Waystar Holding Corp
WAY
$5B
$5.44M 0.03%
+264,900
New +$5.57M
BC icon
64
Brunswick
BC
$4.71B
$5.14M 0.02%
+61,000
New +$4.89M
GNTX icon
65
Gentex
GNTX
$4.81B
$5.03M 0.02%
+199,000
New +$4.71M
IDXX icon
66
Idexx Laboratories
IDXX
$41.7B
$4.74M 0.02%
+9,000
New +$5.05M
PRME icon
67
Prime Medicine
PRME
$673M
$4.58M 0.02%
1,240,843
– –
CMC icon
68
Commercial Metals
CMC
$7.61B
$4.2M 0.02%
+67,000
New +$4.71M
JATT
69
JATT II Acquisition Corp
JATT
$95.5M
$3.41M 0.02%
+300,000
New +$3.19M
SGMT icon
70
Sagimet Biosciences
SGMT
$679M
$3.21M 0.01%
+415,000
New +$2.82M
SMC
71
Summit Midstream
SMC
$474M
$1.66M 0.01%
58,214
– –
TEVA icon
72
Teva Pharmaceuticals
TEVA
$42.7B
$1.36M 0.01%
40,000
-314,000
-89% -$10.5M
RVMDW icon
73
Revolution Medicines Inc Warrant
RVMDW
$132M
$1.13M 0.01%
120,085
– –
COGT icon
74
Cogent Biosciences
COGT
$6.06B
$658K ﹤0.01%
17,000
– –
ANNAW
75
AleAnna Inc Warrant
ANNAW
$9.74M
$297K ﹤0.01%
990,000
– –
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Farallon Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.

Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
  • Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.